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SUMMARY 
 
Twelve SPF chickens with moderately high-titred HI antibodies of 7 log2 and 8 log2achieved at week 4 post-vaccination after a 
single vaccination with an inactivated whole-H5N2 virus vaccine developed at Veterinary Research Institute, Ipoh were selected for 
efficacy and shedding studies. The H5N2 vaccine virus shares approximately 88.2% homology to the HA gene of the H5N1 challenge 
virus. The chickens with moderately high titred-HI humoral antibodies provided 100% protection against mortality and morbidity after 
challenged with a lethal highly pathogenic H5N1 Malaysian strain.  The challenge H5N1 virus was reisolated from pooled cloacal swabs 
of chickens with HI titres of 7 log2 and 8 log2 at 3 days post challenged, however, was not reisolated from the pooled oropharyngeal 
swabs. The virus titre at reisolation was 101EID50/0.1 ml in pooled cloacal samples from both the 7 log2 and 8 log2 HI titred-chickens. 
There was no challenge H5N1 virus reisolated from chickens with HI titre of 9 log2. This study demonstrated that chickens with 
moderately high HI humoral antibodies protect chickens against clinical disease and mortality did not fully prevent infection, however, 
was able to reduce virus shed via the cloaca and oropharynx.  
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INTRODUCTION 
 
The H5N1 epizootic outbreak has resulted in the 
increase in the vaccination against H5N1 in poultry 
population of countries such as China, Italy, Mexico, 
Pakistan and Indonesia. For these countries, vaccination 
seemed to be one of the principal means of combating 
highly pathogenic (HP) avian influenza, as vaccination can 
control infection and reduce the incidence of clinical 
disease, thus reduce viral load in the environment (Swayne 
and Suarez, 2007; Capua et al., 2007). As inactivated HP 
H5N1 vaccines are not feasible to be made into vaccines, 
due to reasons, such as incomplete inactivation which may 
result in disease and spread, and difficulty in differentiating 
from wild field and vaccine strains,  inactivated vaccines 
based on reverse genetics and heterologous HA and NA 
antigens are therefore the best options. Inactivated vaccines, 
however, seemed to give variable results and booseters need 
to be given to achieve high immune responses. A study by 
Terrigino et al. (2006) showed that vaccination with an 
inactivated H5N9 subtype vaccine at 3 weeks and 
boostering at 7 weeks of age induced a very high immune 
response, GMT 10.3 log2. This immune response was 
protective against challenge with 10
6
 EID50/0.1 ml of the 
highly pathogenic A/chicken/Yamaguchi/7/2004 H5N1 
subtype and suppress shedding after challenge. Studies in 
ducks and geese also showed variable results. A study on an 
inactivated reverse genetic (RG) vaccine H5N1/PR8 for  
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ducks and geese, where the HA gene implicated in virulence 
is replaced with a non-pathogenic H5 gene, HI antibodies 
were only detectable at week 1 post vaccination (pv), and 
by 6 weeks pv, the antibody rose to a high HI titre of 1024 
and waned off to a titre of 16 by 43 weeks (Tian et al., 
2005). A bivalent inactivated vaccine of H5N9 +H7N1and a  
monovalent H5N3 which was given to 1 day old and 3 
weeks old ducks , induced only low titres of 2 log2 - 3 log2 
and 3 log2 – 6 log2 respectively, which was achieved at 
week 2 post vaccination. Despite the failure to stimulate 
significant HI titres, the bivalent vaccine did offer 
protection however, did not stop virus replication as seen in 
the seroconversion or the rise in antibody titres following 
challenge.  The monovalent H5N3 vaccine, however, 
provided solid protection with no evidence of shedding of 
the challenge virus and no serological response to the H5N1 
challenge virus (Middleton et al., 2007). Lee et al. (2007), 
however, showed that doses or quantity of antigen of the 
same HA subtype and boostering are important for 
protective efficacy of the vaccine against H5N1 challenge. 
In their study, they showed that one dose of 128 HAU and 
64 HAU homologous H5 vaccine induced 100% and 50% 
protection respectively.  Virus shedding was prevented with 
the 128 HAU but not with the 64 HAU antigen quantities. 
They also showed that two doses at a 3-week interval with 
64 HAU as well as an extra one dose of 1024 HAU of 
heterologous H5N3 vaccine provided 100% protection and 
prevent viral shedding completely. This is in agreement 
with studies by Swayne et al. (1999) who showed that there 
was a correlation between the antigen quantity or antigenic 
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content and protective efficacy of the vaccine. In contrast, 
others reported that high virus titres can still be present in 
vaccinated chickens that are protected against clinical 
disease (Maas et al., 2009) where in one study with H9N2 
vaccine, after vaccination with as much as 128 or 1024 
HAU low pathogenic (LP) H9N2 virus and despite the 
induction of high antibody titres, the LP H9N2 challenge 
virus could still be isolated from the vaccinated chickens 
(Choi et al., 2008). 
The molecular and antigenic similarities of 96.8 - 100% 
between the individual H5 avian influenza strains were 
sufficient to elicit solid cross protection against emerging 
HP H5N1 viruses, however, there was no positive 
correlation between sequence identity and the ability to 
reduce the quantity of challenge virus shed. For example, a 
study by Kumar et al. (2007) showed that chickens with 
high HI titres (> 640) elicited by a reverse genetics H5N3 
avian influenza isolate and challenged with the original 
H5N3 virus i.e 100% similarity in the HA genes, did not 
result in sterile immunity as virus can be reisolated from at 
least 1/16 chickens with high antibody titres (HI:160 - 640).  
The purpose of the study was, therefore, to determine 
the protection and effect on challenge virus shedding by 
chickens with moderately high titred-antibody as induced 
by a heterologous whole-H5N2 virus vaccine strain, with an 
HA gene homology of 88.2% with the challenge H5N1 
virus. The practical implication of this trial is that, if 
protection is afforded and is effective in decreasing virus 
excretion at such moderately high titres, this vaccine need to 
be further improved eg. in its antigenic content during 
delivery, formulation with effective oil adjuvants and 
boostering effect, so as this vaccine can induced high titres 
in at least 80% of chickens in  a single  or multiple 
vaccination.   
 
MATERIALS AND METHODS 
 
Viruses 
 
The Malaysian vaccine virus strain A/duck/Malaysia 
/8443/04 H5N2 isolated from ducks was developed as an 
inactivated whole-virus oil emulsion vaccine at Veterinary 
Research Institute, Ipoh. The pre-activation titre was 
10
7.3
EID50/0.1ml. Cleavage site sequencing and the IVPI 
showed that the virus is of low pathogenicity. Table 1 
showed the comparison between the H5N2 vaccine and 
H5N1 challenged strain. The challenge virus strain used 
was A/chicken/Malaysia/5858/04 H5N1. 
Compared to the challenge virus, the percentage 
sequence identity of the HA gene of the vaccine H5N2 and 
challenge virus H5N1 was 88.2% by nucleotide sequence 
and 90% by amino acid sequence. As for the comparison of 
the HAI segment, the nucleotide sequence similarities were 
88.3 % and by amino acid sequence was 87.7% (Sharifah et 
al., 2012). 
 
 
Table 1: Characterization of the H5N2 vaccine virus strain 
compared to the challenged H5N1 virus 
 
Comparison Percentage 
HA gene 
Sequence identity 
HAI segment 
Nucleotide 
sequence 
88.2 88.3 
 
Amino-acid 
sequence 
90 87.7 
 
 
Vaccination of SPF birds and selection of chickens with 
high HI titre ≥ 128 
 
Thirty two-week old SPF chickens (raised in Veterinary 
Research Institute, Ipoh, Malaysia) were vaccinated with 
200µl of the H5N2 vaccine via the SQ route. In our studies 
(Sharifah et al., 2012) we found that 100% of birds had 
seroconverted by week 4 post vaccination and demonstrated 
the highest titres at this week of vaccination. At week 4 post 
vaccination, twelve chickens with high HI antibody titres of 
7 log2 - 9 log2 (128 - 512) were selected, tagged and 
challenged with 200µl H5N1 virus by the intranasal route 
with 10
6.0 
EID50/0.1ml of the virus. This dose was earlier 
shown to induce full mortality of unvaccinated controls with 
a MDT of 36 - 48 hr. 
Challenged of the chickens with HPAI H5N1 virus was 
conducted in a negative pressure isolator cabinet ventilated 
with HEPA-filtered air in a NATA-certified biosafety level-
3 facility of VRI, Ipoh. Water and feed were provided at 
libitum. Three SPF birds of the same batch and age that had 
not been vaccinated with the H5N2 vaccine were used as 
the challenge control. Mean Death Time was determined for 
all birds that died.  
 
HI assay 
 
The detection of antibodies after vaccination was 
studied by the HI assay performed according to the WHO 
manual on Animal Influenza diagnosis and Surveillance 
(WHO/CDS/CSR/NCS/2002.5). Serum samples were 
diluted 2 fold, with the initial serum dilution at 1:2. Titres > 
3 log2 were considered positive. The serological response 
was evaluated for all birds before and after vaccination. The 
HI test was performed in V-bottom 96 well microtiter plates 
with 8 HAU/50µl of homologous inactivatedH5N1 antigen 
per well.  
 
Oropharyngeal and cloacal shedding of virus 
 
Clinical signs were monitored daily for one week post-
challenged. Cloacal and oropharyngeal swabs of each of the 
chickens were sampled at 3 days post challenge for virus 
reisolation. The cloacal and oropharyngeal swabs of 
chickens with similar HI titres (i.e birds with HI titres of 7 
log2 (128), 8 log2 (256) and 9 log2 (512) were pooled and 
virus isolation performed in 9-11 day SPF embryonated 
eggs using standard procedures (Krauss et al., 2004). 
Personnel of the Virology Lab of VRI who conducted the 
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re-isolation of the virus were blinded by the treatment 
group. The presence of H5N1 challenge virus in the 
allantoic fluid was detected using the HA test and 
confirmed using specific H5-haemagglutination-inhibition 
test. Three passages were undertaken and HA test 
performed at each passage before the samples were 
considered negative. Positive viral titres were expressed as 
EID50/0.1ml. 
 
RESULTS 
 
Shedding of challenged virus  
 
Twelve chickens with high HI antibody titres of 7log2-9 
log2 (128-512) did not show any clinical signs and survived 
the challenged. Table 2 showed the HI titre at which the 
chickens were challenged, the morbidity, mortality and 
virus re-isolation data. H5N1 virus was however, isolated 
from the pooled cloacal swabs of the group with HI titre of 
128 and 256, but not from the pooled oropharyngeal swabs.  
No virus was isolated from the pooled samples of the other 
two groups i.e. the group with HI titre: 256 and HI titre: 
512.  The H5N1 virus was only detectable at the third 
passage in SPF eggs and the titre was calculated to be 1 log 
10 EID50/0.1ml. This shows that chicken/s in the HI titre: 
128 and 256 group of chickens shed detectable amount of 
challenge virus by the cloacal route. This is a small study 
limited by space of the BSL-3 facility, to make statistical 
inferences of protection associated with these moderately 
high titres not possible.  
 
DISCUSSION  
 
From our previous study (Sharifah et al., 2012), we 
showed that with a single vaccination of commercial birds  
with the inactivated whole H5N2 vaccine that was 
developed at VRI, Ipoh, the HI antibody titers did not rise to 
high levels. The highest HI titre achieved was 9 log2 (512) 
and only in 4% (1/25) of vaccinated chickens. Titres of 7-9 
log2 (128-512) was only achieved at week 4 post 
vaccination (Sharifah et al., 2012). In this study, out of the 
30 SPF chickens vaccinated only 40% (12/30) achieved a 
titre 7-9 log2. From the 30 vaccinated birds, only 5, 4 and 3 
chickens attained an HI titre of 128, 256 and 512 
respectively, at week 4 post vaccination.  In this study, we 
inoculated 30 SPF birds with the aim of selecting 
moderately high HI titred chickens for efficacy and 
shedding evaluation.  From the 30 vaccinated birds, only 5, 
4 and 3 chickens attained an HI titre of 128, 256 and 512 
respectively, at week 4 post vaccination.  In this experiment 
we wanted to determine whether chickens with HI titres of 
7-9 log2 (maximum titres achieved using this vaccine in a 
single vaccination) can still protect birds against morbidity, 
mortality and shedding. There were no clinical signs 
observed in chickens after challenged.  However, chickens 
seemed to excrete virus at 3 days post challenged via the 
cloacal route. The loads of virus isolated from the cloaca 
however, was very much reduced (10
1
 EID50/0.1 ml) 
compared to the load of virus reisolated from the cloaca and 
also the oropharynx of the challenged control unvaccinated 
groups. This study confirms that heterologous vaccine and 
moderately high titred responses protected against clinical 
signs and mortality, and significantly decreased shedding 
after intranasal challenge, but they did not fully prevent 
infection or provide sterile immunity. This inactivated 
H5N2 vaccine sharing an 88.2 % nucleotide and 90% amino 
acid similarities with the HA gene and protein respectively 
of the challenge H5N1 virus, was able to protect chickens 
with moderately high HI titres of 7 - 9 log2. Although this 
vaccine protected chickens with moderately high titred-HI 
antibody against challenged, chickens with lower HI titres 
were not protected (Sharifah et al., 2012). 
 
Table 2: Response of 12 SPF chickens (at 6 weeks old) with moderately high HI titres after a single vaccination with the 
H5N2 inactivated vaccine and challenged with pathogenic H5N1 virus 
 
Challenged time No of 
birds 
HI titre No. of 
morbidity 
No of 
mortality 
Isolation of H5N1 from pooled samples 
(titre of virus) 
Week 4 post-
vaccination 
(6 weeks old) 
 
5 
 
128 
 
0/12 0/12 H5N1 virus was reisolated at the third 
passage in SPF embryonated eggs (EE) 
only from the pooled cloacal swabs of 
chickens with HI titre of 128 and 256.  
 
Virus load in the cloacal swabs from 
chickens of both HI titres was 101 
EID50/0.1 ml 
4 256 
 
3 512 
 
Controls 
6-wks old SPF 
chickens 
3 < 2 3/3 3/3 
 
H5N1 virus was reisolated from the pooled 
samples from cloacal swabs and 
orpharyngeal swabs of dead chickens. 
 
H5N1 virus reisolated at 1st passage in 
SPF EE. Virus load was 103.6EID50/0.1ml 
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Boostering might result in chickens achieving much 
higher HI titres, however, this was not done for this 
vaccine.  
All the studies showed that no matter how high the 
titre achieved by vaccination with a heterologous NA 
vaccine, high titres still cannot afford sterile immunity 
to all the birds. Some of the reasons for this could be 
due to such factors as host genetic and immune system, 
immunosuppression by other diseases the level of 
virulency of HPAI strains and partial cross protection, 
where for example, any one virus that escape the 
immunity, has the ability to multiply and replicate in 
the susceptible cells of the oropharynx and the 
intestines, i.e. areas not reachable by humoral HI 
antibodies.   
In this study we were not able to isolate virus from 
the oropharynx, however, many workers including 
Swayne et al. (1999) and Kumar et al. (2007) were 
able to isolate the challenge virus from the oropharynx. 
The load of virus in the oropharynx was shown to be 
higher than in the cloaca. According to Swayne, a 
100% homology between the haemagglutinin of 
vaccine and the challenge virus can protect birds 
against clinical disease but did not result in the 
prevention of infection by the challenge virus and 
shedding from the oropharynx. The differences in total 
amino acid sequence of the HA1 protein of vaccines, 
however, was also shown not to correlate with 
reductions in challenged virus titres shed from the 
oropharynx or cloaca. 
Many workers have reported that vaccination 
cannot prevent infection whether the vaccine is 
heterologous or homologous to the virus challenged 
strain, therefore it is essential that as long as 
vaccination decreases virus excretion to levels that are 
insufficient for virus transmission within poultry 
flocks, than the vaccine should be acceptable. The 
variable results achieved by the various workers 
reflects the diverse variables used in each of the studies 
which include the  use of different vaccines, and 
challenge viruses, different routes of administration of 
challenge viruses and the different doses and antigenic 
content of the vaccine at delivery. 
Controlling of widespread transmission of the 
H5N1 virus is a major issue in countries where H5N1 
is present and the use of inactivated vaccines is an 
effective control strategy (Swayne and Suarez, 2000). 
However, for eradication purposes, a mechanism for 
the differentiation between infected and vaccinated 
chickens needs to be introduced (Capua, 2007). It is 
clear that, because of the human health implications of 
AI infections, control plans must aim at the elimination 
of the infection, based on any strategy that is chosen.  
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